Mithra Reports 2016 Annual Results

  • Significant operational progress across our transformational E4 (Estetrol) programs and our complex therapeutic solutions positions Mithra for long-term international growth
  • Mithra is accelerating investment and business development activities for its highly promising E4-based pipeline, including the 5th generation oral contraceptive Estelle® and next generation menopause therapy Donesta®
  • Phase III Estelle® oral contraceptive studies initiated in Europe and US

Liège, Belgium, 2 March 2017 – Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces its results for the year ended 31 December 2016, prepared in accordance with IFRS.